Bevacizumab biosimilar - AbbVie/Amgen
At a glance
- Drug Originator Amgen; Watson Pharmaceuticals
- Drug Licenced by Daiichi Sankyo Company
- Drug Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
- USA Patent Applicants AMGEN INC
- USA Patents 2
- BLAs 1
- International Patents 5

Disclaimer